Psychedelics News

2026 Third Quarter — Legislative Wrap Up

Since the beginning of 2026, at least 23 states have introduced psychedelic legislation, signaling continued momentum and openness in how local and federal leaders address mental health, substance use disorders, and b...

Why chronic low back pain feels 'personal'

Low back pain is the single leading cause of disability worldwide, according to the World Health Organization. For people with chronic low back pain (cLBP) lasting more than 12 weeks, a sudden pain flare triggered by ...

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapyTORONTO, Oct. 06,…

Talking to yourself on psilocybin may be a good sign in alcohol treatment, small study hints

In a small psilocybin trial for alcohol use disorder, people who stayed alcohol-free three months later tended to describe an inner dialogue during their session, while those who returned to drinking talked more about...

Weekly Psychedelic Policy Briefing: October 5, 2026

A DEA judge has paused the hearing on moving all marijuana to Schedule III while he decides whether to admit a GAO report on gaps in federal scheduling procedures. Also this week: New Mexico advocates push back on the...

Psychedelic drugs were once considered ‘revolutionary rocket fuel’, but could they be life-changing medicines?

In Trip Reports, journalist Rich Haridy (a self-confessed ‘psychonaut’) dives into the science of psychedelic medicine and developments in Australia.

What happens when GLP-1s mix with psychedelics? 5 Questions with neuroscientist Ali D. Güler

Güler discusses the emerging research on how GLP-1s affects the brain.

Compass Pathways Is Taking a Page From Johnson & Johnson

Plus the DEA moving five new drugs to Schedule I, the entropic brain theory, and trip killers [...] Read More...

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

MAPS and International Alliance of Psychedelic Therapy Practitioners Announce Partnership to Advance Training for Psychedelic-Assisted Therapy

Washington, D.C., October 5, 2026 – The Multidisciplinary Association for Psychedelic Studies (MAPS) announced a new strategic partnership with the International Alliance of Psychedelic Therapy Practitioners (Psychede...

Psychedelics Restructure the Global Workspace of Consciousness

This preprint reanalysed resting-state brain scans from two crossover studies in healthy volunteers, finding that LSD, psilocybin and mescaline were associated with more model-defined “gateway” regions in frontopariet...

The FDA is seeking public comments and data on early-phase clinical trial designs for ibogaine drug products, including dosing, safety monitoring and oversight.

The FDA’s request for information covers study populations, dose selection and escalation, care settings, safety monitoring, eligibility, stopping rules, informed consent and independent oversight. Comments, data and ...

An Open-Label Multidose Psilocybin Intervention for Obsessive-Compulsive Disorder

In this unblinded randomised waitlist-controlled preprint, 37 people with OCD were assigned to immediate or delayed psilocybin and 30 completed the one-month analysis; a 20 mg session was followed by 30 mg if tolerate...

Psychedelic Research Recap: September 2026

September 2026's psychedelic research recap covers clinical trials, low-dose pharmacology, brain studies, and preclinical mechanisms, with uncertainty kept in view.

Psyence BioMed’s Texas subsidiary has agreed a manufacturing partnership with DEA-registered Benuvia Operations for planned US production of pharmaceutical-grade ibogaine API.

Texas Ibogaine Research Corporation, Psyence BioMed’s wholly owned subsidiary, will work with Benuvia Operations at its Round Rock, Texas facility to manufacture ibogaine API under cGMP standards. The partnership buil...